Azienda Ospedaliero Universitaria Careggi
Welcome,         Profile    Billing    Logout  
 43 Trials 
92 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vannucchi, Alessandro
AMELIORATE, NCT04174612 / 2019-003936-21: AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Recruiting
3
172
Europe
Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD
Gruppo Italiano Malattie EMatologiche dell'Adulto, MYNERVA (MYeloid Neoplasms Research Venture AIRC) programma speciale finanziato dall'AIRC - Associazione Italiana per la, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus
Acute Myeloid Leukemia With FLT3/ITD Mutation
12/22
08/25
NCT06401356: An Extension Study for Patients Previously Enrolled in Studies with Pelabresib

Recruiting
3
50
Europe, US
Pelabresib, CPI-0610
Constellation Pharmaceuticals
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
06/29
06/29
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
ACCESS-EXT, NCT05744921 / 2021-004931-10: A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works.

Recruiting
3
202
Europe, Canada, Japan, RoW
Pozelimab, REGN3918, Cemdisiran, ALN-CC5
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria
02/29
02/29
ENABLE, NCT04763928 / 2020-006114-20: Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax

Active, not recruiting
2
101
Europe
Venetoclax+Decitabine
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Gimema Franco Mandelli Onlus, AbbVie Srl
Acute Myeloid Leukemia
10/24
04/26
POTAMI-61, NCT06397313: RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

Recruiting
2
230
Europe
RVU120, SEL120, Ruxolitinib, RUX
Ryvu Therapeutics SA
Myelofibrosis
06/26
10/27
MPN-COVID, NCT04385160: Myeloproliferative Neoplasms (MPN) and COVID-19

Recruiting
N/A
552
Europe, US, RoW
Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net
Myeloproliferative Neoplasm, COVID
02/22
08/22
NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

Recruiting
N/A
319
Europe
Ropeginterferon alfa-2b, Besremi
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Polycythemia Vera
09/26
12/26
ERNEST-3, NCT06533813: Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

Recruiting
N/A
617
Europe, RoW
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline
Myelofibrosis
12/25
12/28
Mencucci, Rita
NCT06189456: Evaluation of Performance and Safety of Eye Drops With Hyaluronic Acid 0.30% and 0.15%

Recruiting
N/A
100
Europe
BLUgel A, BLUyal A
Fidia Farmaceutici s.p.a.
Dry Eye Syndrome (DES)
07/24
12/24
NCT06641882: Retrospective Chart Review of Patients with Acanthamoeba Keratitis Who Have Received 0.8 Mg/ml Polihexanide

Recruiting
N/A
40
Europe
SIFI SpA
Acanthamoeba Keratitis
06/25
07/25
Sodi, Andrea
RPE65-NHS, NCT04525261: Natural History of Patients With Inherited Retinal Diseases Due to Mutations in RPE65 Gene

Completed
N/A
60
Europe
University of Campania "Luigi Vanvitelli", Retina Italia Onlus
Leber Congenital Amaurosis 2, Retinitis Pigmentosa 20
07/20
07/20
Massacesi, Luca
RED4MS, NCT06430671 / 2022-000801-28: Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

Recruiting
1/2
135
Europe
CLS12311 low, CLS12311 medium, CLS12311 high, uncoupled RBCs
Cellerys AG, Novartis, Scope International AG, Tetec AG, Jung Diagnostics GmbH
Relapsing-remitting Multiple Sclerosis (RRMS)
08/26
03/27
Villa, Gianluca
GlobalARRT, NCT04580680: Extracorporeal Blood Purification Therapy in Critically Ill Patients

Recruiting
N/A
1000
Europe
Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)
Careggi Hospital, University of Florence
Critical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response Syndrome
09/25
09/25
NCT04033224: Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure

Recruiting
N/A
1000
Europe
Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)
Careggi Hospital, University of Florence
Critical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response Syndrome
09/25
09/25
NCT03807414: Development of a Web-based Multicenter Registry on the Use of oXiris Membrane for EBPTs in Critically Ill Patients

Active, not recruiting
N/A
270
Europe
oXiris
Careggi Hospital, University of Florence
Critical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response Syndrome
09/25
09/25
Liesner, Raina
B-Natural, NCT02502409: Natural History Study of Factor IX Treatment and Complications

Active, not recruiting
N/A
550
US
Standard care with blood and urine sample collection
Skane University Hospital, Indiana Hemophilia &Thrombosis Center, Inc., Bioverativ Therapeutics Inc., Swedish Orphan Biovitrum
Factor IX Deficiency
06/19
12/21
Protect-NOW, NCT03695978: Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia a Patients

Recruiting
N/A
200
Europe, Canada, US, RoW
Octapharma
Haemophilia a
06/30
06/30
Livi, Lorenzo
SAFE, NCT02236806: Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab

Active, not recruiting
3
262
Europe
Bisoprolol, Ramipril, Placebo
Azienda Ospedaliero-Universitaria Careggi, University of Florence
Breast Cancer, Cardiotoxicity
06/22
06/22
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
PEGASUS, NCT02799706: Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

Active, not recruiting
3
885
Europe
Degarelix, approved GnRH agonist, Radiotherapy
European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
08/23
06/26
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
EUROPA, NCT04134598 / 2004-003749-42: ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer

Recruiting
3
926
Europe
Breast irradiation (RT), Partial Breast Irradiation (PBI), Whole Breast Irradiation (WBI), Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen, Hormonal therapy
Azienda Ospedaliero-Universitaria Careggi, University of Florence
Breast Cancer
04/25
04/30
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
MP-LALC, NCT03379441: Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC

Not yet recruiting
2
126
Europe
Pembrolizumab Injectable Product
University of Turin, Italy
Non Small Cell Lung Cancer Patients
01/23
01/23
GALAXIES LUNG-201, NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
340
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
10/25
10/28
AVEC-119, NCT06869473: Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, As First-line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with a PD-L1 Combined Positive Score (CPS)≥1≤19.

Recruiting
2
67
Europe
Cetuximab/avelumab
Gruppo Oncologico del Nord-Ovest, Merck Serono S.P.A., Italy, Clinical Research Technology S.r.l.
Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
08/27
02/28
UPSTREAM, NCT03088059 / 2017-000086-74: Biomarker-based Study in R/M SCCHN

Checkmark Data from UPSTREAM trial in combination with monalizumab for SCCHN
Oct 2019 - Oct 2019: Data from UPSTREAM trial in combination with monalizumab for SCCHN
Active, not recruiting
2
340
Europe
Afatinib, Palbociclib, standard of care, IPH2201, Monalizumab, Durvalumab, Niraparib, INCAGN01876
European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Squamous Cell of Head and Neck
06/25
12/25
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Completed
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
01/25
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
ROCK, NCT03520894: Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer

Recruiting
N/A
25
Europe
Neoadjuvant radiotherapy
Azienda Ospedaliero-Universitaria Careggi
Early Breast Cancer
05/22
05/24
AIR Study, NCT06248944: AIOCC Italian Registry on Head and Neck Carcinomas

Recruiting
N/A
7000
Europe
observational-retrospective and prospective
Italian Head&Neck Society
Head and Neck Carcinoma
07/27
07/27
SAFE-FORWARD, NCT04842409: Safety of Ultra-hypofractionated Whole Breast Irradiation After Breast-conserving Surgery

Completed
N/A
50
Europe
Whole breast irradiation
Azienda Ospedaliero-Universitaria Careggi
Breast Cancer, Radiotherapy Side Effect
12/22
12/22
NCT05143268: Acupuncture for Dysphagia in Head and Neck Squamous Cell Carcinoma

Recruiting
N/A
90
Europe
Lorenzo Livi
Head and Neck Squamous Cell Carcinoma
10/23
10/23
NCT04810182: Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Completed
N/A
192
Europe
Regorafenib 40 MG Oral Tablet [STIVARGA]
Istituto Oncologico Veneto IRCCS
Glioblastoma Multiforme
12/23
12/23
E²-RADIatE, NCT03818503: E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

Recruiting
N/A
2000
Europe, RoW
European Organisation for Research and Treatment of Cancer - EORTC
Cancer
04/26
04/26
SPRINT, NCT05761054: Sarcoma Preoperative Radiation With Simultaneous INTegrated Boost

Recruiting
N/A
33
Europe
RT
Azienda Ospedaliero-Universitaria Careggi
Soft Tissue Sarcoma
07/25
07/27
STARR, NCT05455736: STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence After prostatectomy-a Prospective Observational Study

Recruiting
N/A
90
Europe
Stereotactic salvage radiotherapy for macroscopic prostate bed relapse
Azienda Ospedaliero-Universitaria Careggi
Prostate Cancer, Relapse
07/23
07/24
PSICHE, NCT05022914: PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-

Recruiting
N/A
180
Europe
Azienda Ospedaliero-Universitaria Careggi
Prostate Cancer, Biochemical Relapse Fo Malignant Neoplasm of Prostate, Prostate Adenocarcinoma, Prostate Cancer Recurrent
01/24
01/27
Meattini, Icro
SAFE, NCT02236806: Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab

Active, not recruiting
3
262
Europe
Bisoprolol, Ramipril, Placebo
Azienda Ospedaliero-Universitaria Careggi, University of Florence
Breast Cancer, Cardiotoxicity
06/22
06/22
EUROPA, NCT04134598 / 2004-003749-42: ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer

Recruiting
3
926
Europe
Breast irradiation (RT), Partial Breast Irradiation (PBI), Whole Breast Irradiation (WBI), Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen, Hormonal therapy
Azienda Ospedaliero-Universitaria Careggi, University of Florence
Breast Cancer
04/25
04/30
IMPORTANT, NCT06044623: Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients

Recruiting
3
495
Europe
CDK 4/6 inhibitors, Endocrine therapy
Region Örebro County, University of Patras, University of Florence, Azienda USL Toscana Centro, Helsinki University Central Hospital, Institute for Medical Technology Assessment - the Netherlands, Security Labs Consulting Limited, Circular Economy Foundation, Universidad Nacional de Educación a Distancia, Hellenic Cooperative Oncology Group, University Hospital, Akershus, Uppsala County Council, Sweden, Hospital Clinic of Barcelona, Phaze Clinical Research & Pharma Consulting, Bröstcancerförbundet, Eunomia Ltd, University of Applied Sciences and Arts Northwestern Switzerland, CareAcross Ltd, Örebro University, Sweden
Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life, Toxicity, Older Patients
10/28
05/29
TREAT ctDNA, NCT05512364: Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse

Recruiting
3
220
Europe
Elacestrant, Tamoxifen, Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25 MG
European Organisation for Research and Treatment of Cancer - EORTC, Breast International Group, Menarini Group
ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
07/28
05/30
ROCK, NCT03520894: Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer

Recruiting
N/A
25
Europe
Neoadjuvant radiotherapy
Azienda Ospedaliero-Universitaria Careggi
Early Breast Cancer
05/22
05/24
SAFE-FORWARD, NCT04842409: Safety of Ultra-hypofractionated Whole Breast Irradiation After Breast-conserving Surgery

Completed
N/A
50
Europe
Whole breast irradiation
Azienda Ospedaliero-Universitaria Careggi
Breast Cancer, Radiotherapy Side Effect
12/22
12/22
PALMARES-2, NCT06805812: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian Study

Recruiting
N/A
3500
Europe
Palbociclib, Ribociclib, Abemaciclib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, European Institute of Oncology, Italy, Humanitas Research Hospital IRCCS, Rozzano-Milan, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, OSPEDALE ASST CREMONA, IOV Oncologico Veneto Padova, ASST Fatebenefratelli Sacco, IRCCS Fondazione Salvatore Maugeri, Pavia, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, A.O.U. Federico II, Napoli, San Raffaele University Hospital, Italy, Centro di Riferimento Oncologico - Aviano, Azienda Socio-Sanitaria Territoriale Lariana, Azienda ULSS 3 Serenissima, Ospedale di Mirano, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Fondazione IRCCS Policlinico San Matteo di Pavia, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliero-Universitaria Careggi, Humanitas, Istituto Clinico Catanese, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Fondazione Policlinico Universitario Campus Bio-Medico, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma, Breast Diseases, Breast Neoplasms, Breast Neoplasms, Male, Breast Cancer, Breast Cancer With Metastatic Bone Disease, Breast Cancers, Breast Neoplasm, Breast Tumors, HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer, HR+ Advanced or Metastatic Breast Cancer, HR+/HER2- Breast Cancer, HRpos Breast Neoplasms, HR-positive, HER2-negative Advanced Breast Cancer, HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer, HR-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Breast Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone Receptor Positive Metastatic Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer, Hormone Receptor Negative Breast Cancer, Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer, Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Hormone Receptor (HR)-Positive Breast Cancer, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Palbociclib, Ribociclib, Abemaciclib, CDK4/6 Inhibitor, CDK4/6 Inhibitors
12/30
12/40
GIM29-GIMOMIC, NCT06871501: "Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

Not yet recruiting
N/A
1000
Europe
Consorzio Oncotech
Breast Cancer
05/25
11/26
Antonuzzo, Lorenzo
JS001-027-III-HCC, NCT04523493 / 2020-004437-20: Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Active, not recruiting
3
530
Europe, RoW
Toripalimab combined with Lenvatinib, Placebo combined with Lenvatinib
Shanghai Junshi Bioscience Co., Ltd., Shanghai Junshi Biosciences Co., Ltd
Advanced Hepatocellular Carcinoma (HCC)
05/25
09/26
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
PANThEON, NCT06897644: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Recruiting
3
340
Europe
Oxaliplatin, Irinotecan (CPT-11), Leucovorin, 5-FU (5-fluorouracil), gemcitabine, Nab-paclitaxel
Gruppo Oncologico del Nord-Ovest, Rising Tide Foundation
Pancreatic Adenocarcinoma Advanced or Metastatic
01/29
01/30
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Colorectal Neoplasms
04/26
07/29
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting
3
756
Europe, US, RoW
Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Limited-stage Small Cell Lung Cancer (LS-SCLC)
07/27
07/29
SENECA, NCT03387592 / 2016-000767-17: CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

Terminated
2
53
Europe
CPT-11, Calcio levofolinate, 5-Fluorouracil, Capecitabine, Temozolomide
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Neuroendocrine Carcinoma
02/22
02/22
DUPLE, NCT06418087: Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)

Recruiting
2
49
Europe
Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI], Carboplatino AHCL 10 mg/ml Concentrate for solution for infusion, Etoposide 20 mg/ml Concentrate for solution for infusion
Gruppo Oncologico Italiano di Ricerca Clinica
Pulmonary Large-cell Neuroendocrine Carcinoma
12/26
12/26
NCT02687958: Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin

Active, not recruiting
2
30
Europe
Everolimus, Afinitor
Gruppo Oncologico Italiano di Ricerca Clinica, Novartis
Neuroendocrine Carcinoma
12/22
12/23
NCT04579679 / 2020-006118-19: Open-Label Surufatinib in European Patients with NET

Completed
2
78
Europe, US
Surufatinib, HMPL-012, sulfatinib
Hutchmed
Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
10/24
10/24
ALK-PPL, NCT06378892: A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Recruiting
2
45
Europe
Lorlatinib
Centro di Riferimento Oncologico - Aviano
Non Small Cell Lung Cancer Metastatic, ALK Gene Mutation
05/28
05/28
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
CAVE 2, NCT05291156: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Recruiting
2
173
Europe
Cetuximab, Erbitux, Avelumab, Bavencio
University of Campania "Luigi Vanvitelli"
Metastatic Colorectal Cancer
07/25
07/25
AxIn, NCT05817903 / 2022-001150-35: Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Recruiting
2
118
Europe
Axitinib, Inlyta, Nivolumab
Consorzio Oncotech, Pfizer
Metastatic Renal Cell Carcinoma
04/26
04/27
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Active, not recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
01/26
03/26
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Terminated
1
28
Europe, RoW
BBP-398, sotorasib
Navire Pharma Inc., a BridgeBio company, Amgen
Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
08/24
08/24
Key-Early, NCT06467383: A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

Recruiting
N/A
600
Europe
MSD Italia S.r.l., YGHEA, CRO Division of Ecol Studio spa
Non-small Cell Lung Cancer, NSCLC, NSCLC, Stage III, NSCLC, Stage I
06/25
06/25
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26
Fanelli, Fabrizio
NCT05971394: IBS Titan™ Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System Clinical Trial

Recruiting
N/A
100
Europe
Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
Biotyx Medical (Shenzhen) Co., Ltd., VascuScience GmbH, Mediolanum Cardio Research Srl, Euroimage Research Srl
Infrapopliteal Lesions, Critical Limb Ischemia
01/26
07/26
Molinari, Angelo Claudio
PedNet, NCT02979119: The European Paediatric Network for Haemophilia Management ( Registry)

Recruiting
N/A
4000
Europe, Canada, RoW
PedNet Haemophilia Research Foundation, Lund University Hospital
Factor VIII Deficiency, Factor IX Deficiency
12/29
12/29
Castaman, Giancarlo
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Completed
3
38
Europe, US, RoW
rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease (VWD)
01/25
01/25
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
34
Europe, US, RoW
von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
01/25
01/25
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated
2
60
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B
11/24
02/25
PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated
N/A
108
Europe, Canada, US, RoW
No Intervention
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B
11/24
11/24
PedNet, NCT02979119: The European Paediatric Network for Haemophilia Management ( Registry)

Recruiting
N/A
4000
Europe, Canada, RoW
PedNet Haemophilia Research Foundation, Lund University Hospital
Factor VIII Deficiency, Factor IX Deficiency
12/29
12/29
Protect-NOW, NCT03695978: Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia a Patients

Recruiting
N/A
200
Europe, Canada, US, RoW
Octapharma
Haemophilia a
06/30
06/30
Romagnoli, Stefano
ALBIOSS-BAL, NCT03654001 / 2018-001582-16: ALBumin Italian Outcome Septic Shock-BALANCED Trial (ANCED)

Completed
3
1319
Europe
Albumin, Balanced, Ringer Lactate, Ringer Acetate, Crystalsol
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Istituto Di Ricerche Farmacologiche Mario Negri
Septic Shock
10/24
01/25
DYNAMIC, NCT04584203: Diastolic dYsfunctioN AssessMent in critICally Ill Patients

Recruiting
N/A
297
Europe
Bedside Echocardiography, Spontaneuos breathing trial, Bedside Echocardiography_1, Baseline Echo_1, Bedside Echocardiography_2, Echo_2, Bedside Echocardiography_3, Echo_3, Bedside Echocardiography_4, Echo_4
Humanitas Clinical and Research Center
Critical Illness, Diastolic Dysfunction, Diastolic Heart Failure, Weaning Failure, Mechanical Ventilation Complication
06/22
06/22
HISTAP, NCT05637606: HIgh Versus STAndard Blood Pressure Target in Hypertensive High-risk Patients Undergoing Major Abdominal Surgery

Recruiting
N/A
636
Europe
Ephedrine, Ephedrine bolus, Norepinephrine, norepinephrine infusion, Etilefrine Hydrochloride bolus, Use of pulse pressure and stroke volume variation (PPV and SVV); use of Mini Fluid Challenge (mini_FC), Hemodynamic optimization
Humanitas Clinical and Research Center, Societa Italiana Anestesia Analgesia Rianimazione e Terapia Intensiva
Blood Pressure, Complication,Postoperative, Intraoperative Hypotension
04/25
05/25
Desideri, Isacco
MIRAGE, NCT06275919: Regorafenib for Recurrent Grade 2 and 3 Meningioma ( Trial)

Recruiting
2
104
Europe
Regorafenib 40 MG Oral Tablet, Local Standard of Care
Istituto Oncologico Veneto IRCCS, Bayer
Meningioma, Malignant
12/26
03/27
Francolini, Giulio
ROCK, NCT03520894: Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer

Recruiting
N/A
25
Europe
Neoadjuvant radiotherapy
Azienda Ospedaliero-Universitaria Careggi
Early Breast Cancer
05/22
05/24
Cataldo, Vanessa Di
ROCK, NCT03520894: Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer

Recruiting
N/A
25
Europe
Neoadjuvant radiotherapy
Azienda Ospedaliero-Universitaria Careggi
Early Breast Cancer
05/22
05/24
Resta, Marco
NCT04033224: Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure

Recruiting
N/A
1000
Europe
Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)
Careggi Hospital, University of Florence
Critical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response Syndrome
09/25
09/25
NCT03807414: Development of a Web-based Multicenter Registry on the Use of oXiris Membrane for EBPTs in Critically Ill Patients

Active, not recruiting
N/A
270
Europe
oXiris
Careggi Hospital, University of Florence
Critical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response Syndrome
09/25
09/25
Gori, Noela
EUROPA, NCT04134598 / 2004-003749-42: ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer

Recruiting
3
926
Europe
Breast irradiation (RT), Partial Breast Irradiation (PBI), Whole Breast Irradiation (WBI), Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen, Hormonal therapy
Azienda Ospedaliero-Universitaria Careggi, University of Florence
Breast Cancer
04/25
04/30
NCT05143268: Acupuncture for Dysphagia in Head and Neck Squamous Cell Carcinoma

Recruiting
N/A
90
Europe
Lorenzo Livi
Head and Neck Squamous Cell Carcinoma
10/23
10/23
Rotella, Francesco
SUSCA, NCT04832178: Sumor as Adjuvant Therapy in Treatment-resistant Major Depression

Recruiting
4
102
Europe
SUMOR, Placebo
Azienda Ospedaliero-Universitaria Careggi
Major Depressive Disorder
06/24
06/24
Cassioli, Emanuele
SUSCA, NCT04832178: Sumor as Adjuvant Therapy in Treatment-resistant Major Depression

Recruiting
4
102
Europe
SUMOR, Placebo
Azienda Ospedaliero-Universitaria Careggi
Major Depressive Disorder
06/24
06/24
Busatta, Daniele
SUSCA, NCT04832178: Sumor as Adjuvant Therapy in Treatment-resistant Major Depression

Recruiting
4
102
Europe
SUMOR, Placebo
Azienda Ospedaliero-Universitaria Careggi
Major Depressive Disorder
06/24
06/24
Voltolini, Luca
NCT03310125 / 2017-003836-35: Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)

Completed
3
3209
Europe, Canada, US, RoW
Colchicine, Placebo
Population Health Research Institute, Hamilton Health Sciences Corporation
Atrial Fibrillation, Atrial Flutter, Myocardial Injury After Non-Cardiac Surgery
07/23
07/23
Lorenzo, Pelagatti
FBS-ASaP, NCT06511583: Fibrobronchoscopy in ASpiration Pneumonia in the Emergency Department

Recruiting
N/A
100
Europe
Laryngotracheal Aspiration Procedure Using a Probe in the Emergency Department, Aspiration Procedure Using Fibrobronchoscopy in the Emergency Department
Azienda Ospedaliero-Universitaria Careggi
Aspiration Pneumonia, Bronchoscopy
02/27
03/27
HCAPPED-I, NCT06506617: HCAPPED I: HCAP-Pcr in Emergency Department

Recruiting
N/A
93
Europe
Azienda Ospedaliero-Universitaria Careggi
Pneumonia, Bronchoalveolar Lavage, Antimicrobial Treatment, Sputum
07/25
01/26
Masi, Salvatore De
REGRASP, NCT06620536: Restoring Hand Function in Patients with Tetraplegia by Intraneural Stimulation of Peripheral Nerves

Not yet recruiting
N/A
2
Europe
Electrical stimulation
Azienda Ospedaliero-Universitaria Careggi, Scuola Superiore Sant'Anna di Pisa
Tetraplegics
01/25
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vannucchi, Alessandro
AMELIORATE, NCT04174612 / 2019-003936-21: AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Recruiting
3
172
Europe
Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD
Gruppo Italiano Malattie EMatologiche dell'Adulto, MYNERVA (MYeloid Neoplasms Research Venture AIRC) programma speciale finanziato dall'AIRC - Associazione Italiana per la, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus
Acute Myeloid Leukemia With FLT3/ITD Mutation
12/22
08/25
NCT06401356: An Extension Study for Patients Previously Enrolled in Studies with Pelabresib

Recruiting
3
50
Europe, US
Pelabresib, CPI-0610
Constellation Pharmaceuticals
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
06/29
06/29
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
ACCESS-EXT, NCT05744921 / 2021-004931-10: A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works.

Recruiting
3
202
Europe, Canada, Japan, RoW
Pozelimab, REGN3918, Cemdisiran, ALN-CC5
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria
02/29
02/29
ENABLE, NCT04763928 / 2020-006114-20: Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax

Active, not recruiting
2
101
Europe
Venetoclax+Decitabine
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Gimema Franco Mandelli Onlus, AbbVie Srl
Acute Myeloid Leukemia
10/24
04/26
POTAMI-61, NCT06397313: RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

Recruiting
2
230
Europe
RVU120, SEL120, Ruxolitinib, RUX
Ryvu Therapeutics SA
Myelofibrosis
06/26
10/27
MPN-COVID, NCT04385160: Myeloproliferative Neoplasms (MPN) and COVID-19

Recruiting
N/A
552
Europe, US, RoW
Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net
Myeloproliferative Neoplasm, COVID
02/22
08/22
NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

Recruiting
N/A
319
Europe
Ropeginterferon alfa-2b, Besremi
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Polycythemia Vera
09/26
12/26
ERNEST-3, NCT06533813: Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

Recruiting
N/A
617
Europe, RoW
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline
Myelofibrosis
12/25
12/28
Mencucci, Rita
NCT06189456: Evaluation of Performance and Safety of Eye Drops With Hyaluronic Acid 0.30% and 0.15%

Recruiting
N/A
100
Europe
BLUgel A, BLUyal A
Fidia Farmaceutici s.p.a.
Dry Eye Syndrome (DES)
07/24
12/24
NCT06641882: Retrospective Chart Review of Patients with Acanthamoeba Keratitis Who Have Received 0.8 Mg/ml Polihexanide

Recruiting
N/A
40
Europe
SIFI SpA
Acanthamoeba Keratitis
06/25
07/25
Sodi, Andrea
RPE65-NHS, NCT04525261: Natural History of Patients With Inherited Retinal Diseases Due to Mutations in RPE65 Gene

Completed
N/A
60
Europe
University of Campania "Luigi Vanvitelli", Retina Italia Onlus
Leber Congenital Amaurosis 2, Retinitis Pigmentosa 20
07/20
07/20
Massacesi, Luca
RED4MS, NCT06430671 / 2022-000801-28: Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

Recruiting
1/2
135
Europe
CLS12311 low, CLS12311 medium, CLS12311 high, uncoupled RBCs
Cellerys AG, Novartis, Scope International AG, Tetec AG, Jung Diagnostics GmbH
Relapsing-remitting Multiple Sclerosis (RRMS)
08/26
03/27
Villa, Gianluca
GlobalARRT, NCT04580680: Extracorporeal Blood Purification Therapy in Critically Ill Patients

Recruiting
N/A
1000
Europe
Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)
Careggi Hospital, University of Florence
Critical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response Syndrome
09/25
09/25
NCT04033224: Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure

Recruiting
N/A
1000
Europe
Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)
Careggi Hospital, University of Florence
Critical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response Syndrome
09/25
09/25
NCT03807414: Development of a Web-based Multicenter Registry on the Use of oXiris Membrane for EBPTs in Critically Ill Patients

Active, not recruiting
N/A
270
Europe
oXiris
Careggi Hospital, University of Florence
Critical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response Syndrome
09/25
09/25
Liesner, Raina
B-Natural, NCT02502409: Natural History Study of Factor IX Treatment and Complications

Active, not recruiting
N/A
550
US
Standard care with blood and urine sample collection
Skane University Hospital, Indiana Hemophilia &Thrombosis Center, Inc., Bioverativ Therapeutics Inc., Swedish Orphan Biovitrum
Factor IX Deficiency
06/19
12/21
Protect-NOW, NCT03695978: Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia a Patients

Recruiting
N/A
200
Europe, Canada, US, RoW
Octapharma
Haemophilia a
06/30
06/30
Livi, Lorenzo
SAFE, NCT02236806: Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab

Active, not recruiting
3
262
Europe
Bisoprolol, Ramipril, Placebo
Azienda Ospedaliero-Universitaria Careggi, University of Florence
Breast Cancer, Cardiotoxicity
06/22
06/22
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
PEGASUS, NCT02799706: Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

Active, not recruiting
3
885
Europe
Degarelix, approved GnRH agonist, Radiotherapy
European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
08/23
06/26
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
EUROPA, NCT04134598 / 2004-003749-42: ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer

Recruiting
3
926
Europe
Breast irradiation (RT), Partial Breast Irradiation (PBI), Whole Breast Irradiation (WBI), Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen, Hormonal therapy
Azienda Ospedaliero-Universitaria Careggi, University of Florence
Breast Cancer
04/25
04/30
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
MP-LALC, NCT03379441: Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC

Not yet recruiting
2
126
Europe
Pembrolizumab Injectable Product
University of Turin, Italy
Non Small Cell Lung Cancer Patients
01/23
01/23
GALAXIES LUNG-201, NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
340
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
10/25
10/28
AVEC-119, NCT06869473: Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, As First-line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with a PD-L1 Combined Positive Score (CPS)≥1≤19.

Recruiting
2
67
Europe
Cetuximab/avelumab
Gruppo Oncologico del Nord-Ovest, Merck Serono S.P.A., Italy, Clinical Research Technology S.r.l.
Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
08/27
02/28
UPSTREAM, NCT03088059 / 2017-000086-74: Biomarker-based Study in R/M SCCHN

Checkmark Data from UPSTREAM trial in combination with monalizumab for SCCHN
Oct 2019 - Oct 2019: Data from UPSTREAM trial in combination with monalizumab for SCCHN
Active, not recruiting
2
340
Europe
Afatinib, Palbociclib, standard of care, IPH2201, Monalizumab, Durvalumab, Niraparib, INCAGN01876
European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Squamous Cell of Head and Neck
06/25
12/25
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Completed
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
01/25
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
ROCK, NCT03520894: Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer

Recruiting
N/A
25
Europe
Neoadjuvant radiotherapy
Azienda Ospedaliero-Universitaria Careggi
Early Breast Cancer
05/22
05/24
AIR Study, NCT06248944: AIOCC Italian Registry on Head and Neck Carcinomas

Recruiting
N/A
7000
Europe
observational-retrospective and prospective
Italian Head&Neck Society
Head and Neck Carcinoma
07/27
07/27
SAFE-FORWARD, NCT04842409: Safety of Ultra-hypofractionated Whole Breast Irradiation After Breast-conserving Surgery

Completed
N/A
50
Europe
Whole breast irradiation
Azienda Ospedaliero-Universitaria Careggi
Breast Cancer, Radiotherapy Side Effect
12/22
12/22
NCT05143268: Acupuncture for Dysphagia in Head and Neck Squamous Cell Carcinoma

Recruiting
N/A
90
Europe
Lorenzo Livi
Head and Neck Squamous Cell Carcinoma
10/23
10/23
NCT04810182: Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Completed
N/A
192
Europe
Regorafenib 40 MG Oral Tablet [STIVARGA]
Istituto Oncologico Veneto IRCCS
Glioblastoma Multiforme
12/23
12/23
E²-RADIatE, NCT03818503: E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

Recruiting
N/A
2000
Europe, RoW
European Organisation for Research and Treatment of Cancer - EORTC
Cancer
04/26
04/26
SPRINT, NCT05761054: Sarcoma Preoperative Radiation With Simultaneous INTegrated Boost

Recruiting
N/A
33
Europe
RT
Azienda Ospedaliero-Universitaria Careggi
Soft Tissue Sarcoma
07/25
07/27
STARR, NCT05455736: STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence After prostatectomy-a Prospective Observational Study

Recruiting
N/A
90
Europe
Stereotactic salvage radiotherapy for macroscopic prostate bed relapse
Azienda Ospedaliero-Universitaria Careggi
Prostate Cancer, Relapse
07/23
07/24
PSICHE, NCT05022914: PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-

Recruiting
N/A
180
Europe
Azienda Ospedaliero-Universitaria Careggi
Prostate Cancer, Biochemical Relapse Fo Malignant Neoplasm of Prostate, Prostate Adenocarcinoma, Prostate Cancer Recurrent
01/24
01/27
Meattini, Icro
SAFE, NCT02236806: Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab

Active, not recruiting
3
262
Europe
Bisoprolol, Ramipril, Placebo
Azienda Ospedaliero-Universitaria Careggi, University of Florence
Breast Cancer, Cardiotoxicity
06/22
06/22
EUROPA, NCT04134598 / 2004-003749-42: ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer

Recruiting
3
926
Europe
Breast irradiation (RT), Partial Breast Irradiation (PBI), Whole Breast Irradiation (WBI), Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen, Hormonal therapy
Azienda Ospedaliero-Universitaria Careggi, University of Florence
Breast Cancer
04/25
04/30
IMPORTANT, NCT06044623: Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients

Recruiting
3
495
Europe
CDK 4/6 inhibitors, Endocrine therapy
Region Örebro County, University of Patras, University of Florence, Azienda USL Toscana Centro, Helsinki University Central Hospital, Institute for Medical Technology Assessment - the Netherlands, Security Labs Consulting Limited, Circular Economy Foundation, Universidad Nacional de Educación a Distancia, Hellenic Cooperative Oncology Group, University Hospital, Akershus, Uppsala County Council, Sweden, Hospital Clinic of Barcelona, Phaze Clinical Research & Pharma Consulting, Bröstcancerförbundet, Eunomia Ltd, University of Applied Sciences and Arts Northwestern Switzerland, CareAcross Ltd, Örebro University, Sweden
Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life, Toxicity, Older Patients
10/28
05/29
TREAT ctDNA, NCT05512364: Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse

Recruiting
3
220
Europe
Elacestrant, Tamoxifen, Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25 MG
European Organisation for Research and Treatment of Cancer - EORTC, Breast International Group, Menarini Group
ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
07/28
05/30
ROCK, NCT03520894: Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer

Recruiting
N/A
25
Europe
Neoadjuvant radiotherapy
Azienda Ospedaliero-Universitaria Careggi
Early Breast Cancer
05/22
05/24
SAFE-FORWARD, NCT04842409: Safety of Ultra-hypofractionated Whole Breast Irradiation After Breast-conserving Surgery

Completed
N/A
50
Europe
Whole breast irradiation
Azienda Ospedaliero-Universitaria Careggi
Breast Cancer, Radiotherapy Side Effect
12/22
12/22
PALMARES-2, NCT06805812: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian Study

Recruiting
N/A
3500
Europe
Palbociclib, Ribociclib, Abemaciclib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, European Institute of Oncology, Italy, Humanitas Research Hospital IRCCS, Rozzano-Milan, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, OSPEDALE ASST CREMONA, IOV Oncologico Veneto Padova, ASST Fatebenefratelli Sacco, IRCCS Fondazione Salvatore Maugeri, Pavia, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, A.O.U. Federico II, Napoli, San Raffaele University Hospital, Italy, Centro di Riferimento Oncologico - Aviano, Azienda Socio-Sanitaria Territoriale Lariana, Azienda ULSS 3 Serenissima, Ospedale di Mirano, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Fondazione IRCCS Policlinico San Matteo di Pavia, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliero-Universitaria Careggi, Humanitas, Istituto Clinico Catanese, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Fondazione Policlinico Universitario Campus Bio-Medico, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma, Breast Diseases, Breast Neoplasms, Breast Neoplasms, Male, Breast Cancer, Breast Cancer With Metastatic Bone Disease, Breast Cancers, Breast Neoplasm, Breast Tumors, HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer, HR+ Advanced or Metastatic Breast Cancer, HR+/HER2- Breast Cancer, HRpos Breast Neoplasms, HR-positive, HER2-negative Advanced Breast Cancer, HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer, HR-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Breast Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone Receptor Positive Metastatic Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer, Hormone Receptor Negative Breast Cancer, Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer, Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Hormone Receptor (HR)-Positive Breast Cancer, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Palbociclib, Ribociclib, Abemaciclib, CDK4/6 Inhibitor, CDK4/6 Inhibitors
12/30
12/40
GIM29-GIMOMIC, NCT06871501: "Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

Not yet recruiting
N/A
1000
Europe
Consorzio Oncotech
Breast Cancer
05/25
11/26
Antonuzzo, Lorenzo
JS001-027-III-HCC, NCT04523493 / 2020-004437-20: Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Active, not recruiting
3
530
Europe, RoW
Toripalimab combined with Lenvatinib, Placebo combined with Lenvatinib
Shanghai Junshi Bioscience Co., Ltd., Shanghai Junshi Biosciences Co., Ltd
Advanced Hepatocellular Carcinoma (HCC)
05/25
09/26
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
PANThEON, NCT06897644: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Recruiting
3
340
Europe
Oxaliplatin, Irinotecan (CPT-11), Leucovorin, 5-FU (5-fluorouracil), gemcitabine, Nab-paclitaxel
Gruppo Oncologico del Nord-Ovest, Rising Tide Foundation
Pancreatic Adenocarcinoma Advanced or Metastatic
01/29
01/30
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Colorectal Neoplasms
04/26
07/29
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting
3
756
Europe, US, RoW
Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Limited-stage Small Cell Lung Cancer (LS-SCLC)
07/27
07/29
SENECA, NCT03387592 / 2016-000767-17: CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

Terminated
2
53
Europe
CPT-11, Calcio levofolinate, 5-Fluorouracil, Capecitabine, Temozolomide
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Neuroendocrine Carcinoma
02/22
02/22
DUPLE, NCT06418087: Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)

Recruiting
2
49
Europe
Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI], Carboplatino AHCL 10 mg/ml Concentrate for solution for infusion, Etoposide 20 mg/ml Concentrate for solution for infusion
Gruppo Oncologico Italiano di Ricerca Clinica
Pulmonary Large-cell Neuroendocrine Carcinoma
12/26
12/26
NCT02687958: Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin

Active, not recruiting
2
30
Europe
Everolimus, Afinitor
Gruppo Oncologico Italiano di Ricerca Clinica, Novartis
Neuroendocrine Carcinoma
12/22
12/23
NCT04579679 / 2020-006118-19: Open-Label Surufatinib in European Patients with NET

Completed
2
78
Europe, US
Surufatinib, HMPL-012, sulfatinib
Hutchmed
Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
10/24
10/24
ALK-PPL, NCT06378892: A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Recruiting
2
45
Europe
Lorlatinib
Centro di Riferimento Oncologico - Aviano
Non Small Cell Lung Cancer Metastatic, ALK Gene Mutation
05/28
05/28
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
CAVE 2, NCT05291156: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Recruiting
2
173
Europe
Cetuximab, Erbitux, Avelumab, Bavencio
University of Campania "Luigi Vanvitelli"
Metastatic Colorectal Cancer
07/25
07/25
AxIn, NCT05817903 / 2022-001150-35: Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Recruiting
2
118
Europe
Axitinib, Inlyta, Nivolumab
Consorzio Oncotech, Pfizer
Metastatic Renal Cell Carcinoma
04/26
04/27
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Active, not recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
01/26
03/26
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Terminated
1
28
Europe, RoW
BBP-398, sotorasib
Navire Pharma Inc., a BridgeBio company, Amgen
Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
08/24
08/24
Key-Early, NCT06467383: A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

Recruiting
N/A
600
Europe
MSD Italia S.r.l., YGHEA, CRO Division of Ecol Studio spa
Non-small Cell Lung Cancer, NSCLC, NSCLC, Stage III, NSCLC, Stage I
06/25
06/25
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26
Fanelli, Fabrizio
NCT05971394: IBS Titan™ Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System Clinical Trial

Recruiting
N/A
100
Europe
Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
Biotyx Medical (Shenzhen) Co., Ltd., VascuScience GmbH, Mediolanum Cardio Research Srl, Euroimage Research Srl
Infrapopliteal Lesions, Critical Limb Ischemia
01/26
07/26
Molinari, Angelo Claudio
PedNet, NCT02979119: The European Paediatric Network for Haemophilia Management ( Registry)

Recruiting
N/A
4000
Europe, Canada, RoW
PedNet Haemophilia Research Foundation, Lund University Hospital
Factor VIII Deficiency, Factor IX Deficiency
12/29
12/29
Castaman, Giancarlo
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Completed
3
38
Europe, US, RoW
rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease (VWD)
01/25
01/25
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
34
Europe, US, RoW
von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
01/25
01/25
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated
2
60
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B
11/24
02/25
PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated
N/A
108
Europe, Canada, US, RoW
No Intervention
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B
11/24
11/24
PedNet, NCT02979119: The European Paediatric Network for Haemophilia Management ( Registry)

Recruiting
N/A
4000
Europe, Canada, RoW
PedNet Haemophilia Research Foundation, Lund University Hospital
Factor VIII Deficiency, Factor IX Deficiency
12/29
12/29
Protect-NOW, NCT03695978: Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia a Patients

Recruiting
N/A
200
Europe, Canada, US, RoW
Octapharma
Haemophilia a
06/30
06/30
Romagnoli, Stefano
ALBIOSS-BAL, NCT03654001 / 2018-001582-16: ALBumin Italian Outcome Septic Shock-BALANCED Trial (ANCED)

Completed
3
1319
Europe
Albumin, Balanced, Ringer Lactate, Ringer Acetate, Crystalsol
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Istituto Di Ricerche Farmacologiche Mario Negri
Septic Shock
10/24
01/25
DYNAMIC, NCT04584203: Diastolic dYsfunctioN AssessMent in critICally Ill Patients

Recruiting
N/A
297
Europe
Bedside Echocardiography, Spontaneuos breathing trial, Bedside Echocardiography_1, Baseline Echo_1, Bedside Echocardiography_2, Echo_2, Bedside Echocardiography_3, Echo_3, Bedside Echocardiography_4, Echo_4
Humanitas Clinical and Research Center
Critical Illness, Diastolic Dysfunction, Diastolic Heart Failure, Weaning Failure, Mechanical Ventilation Complication
06/22
06/22
HISTAP, NCT05637606: HIgh Versus STAndard Blood Pressure Target in Hypertensive High-risk Patients Undergoing Major Abdominal Surgery

Recruiting
N/A
636
Europe
Ephedrine, Ephedrine bolus, Norepinephrine, norepinephrine infusion, Etilefrine Hydrochloride bolus, Use of pulse pressure and stroke volume variation (PPV and SVV); use of Mini Fluid Challenge (mini_FC), Hemodynamic optimization
Humanitas Clinical and Research Center, Societa Italiana Anestesia Analgesia Rianimazione e Terapia Intensiva
Blood Pressure, Complication,Postoperative, Intraoperative Hypotension
04/25
05/25
Desideri, Isacco
MIRAGE, NCT06275919: Regorafenib for Recurrent Grade 2 and 3 Meningioma ( Trial)

Recruiting
2
104
Europe
Regorafenib 40 MG Oral Tablet, Local Standard of Care
Istituto Oncologico Veneto IRCCS, Bayer
Meningioma, Malignant
12/26
03/27
Francolini, Giulio
ROCK, NCT03520894: Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer

Recruiting
N/A
25
Europe
Neoadjuvant radiotherapy
Azienda Ospedaliero-Universitaria Careggi
Early Breast Cancer
05/22
05/24
Cataldo, Vanessa Di
ROCK, NCT03520894: Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer

Recruiting
N/A
25
Europe
Neoadjuvant radiotherapy
Azienda Ospedaliero-Universitaria Careggi
Early Breast Cancer
05/22
05/24
Resta, Marco
NCT04033224: Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure

Recruiting
N/A
1000
Europe
Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)
Careggi Hospital, University of Florence
Critical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response Syndrome
09/25
09/25
NCT03807414: Development of a Web-based Multicenter Registry on the Use of oXiris Membrane for EBPTs in Critically Ill Patients

Active, not recruiting
N/A
270
Europe
oXiris
Careggi Hospital, University of Florence
Critical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response Syndrome
09/25
09/25
Gori, Noela
EUROPA, NCT04134598 / 2004-003749-42: ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer

Recruiting
3
926
Europe
Breast irradiation (RT), Partial Breast Irradiation (PBI), Whole Breast Irradiation (WBI), Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen, Hormonal therapy
Azienda Ospedaliero-Universitaria Careggi, University of Florence
Breast Cancer
04/25
04/30
NCT05143268: Acupuncture for Dysphagia in Head and Neck Squamous Cell Carcinoma

Recruiting
N/A
90
Europe
Lorenzo Livi
Head and Neck Squamous Cell Carcinoma
10/23
10/23
Rotella, Francesco
SUSCA, NCT04832178: Sumor as Adjuvant Therapy in Treatment-resistant Major Depression

Recruiting
4
102
Europe
SUMOR, Placebo
Azienda Ospedaliero-Universitaria Careggi
Major Depressive Disorder
06/24
06/24
Cassioli, Emanuele
SUSCA, NCT04832178: Sumor as Adjuvant Therapy in Treatment-resistant Major Depression

Recruiting
4
102
Europe
SUMOR, Placebo
Azienda Ospedaliero-Universitaria Careggi
Major Depressive Disorder
06/24
06/24
Busatta, Daniele
SUSCA, NCT04832178: Sumor as Adjuvant Therapy in Treatment-resistant Major Depression

Recruiting
4
102
Europe
SUMOR, Placebo
Azienda Ospedaliero-Universitaria Careggi
Major Depressive Disorder
06/24
06/24
Voltolini, Luca
NCT03310125 / 2017-003836-35: Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)

Completed
3
3209
Europe, Canada, US, RoW
Colchicine, Placebo
Population Health Research Institute, Hamilton Health Sciences Corporation
Atrial Fibrillation, Atrial Flutter, Myocardial Injury After Non-Cardiac Surgery
07/23
07/23
Lorenzo, Pelagatti
FBS-ASaP, NCT06511583: Fibrobronchoscopy in ASpiration Pneumonia in the Emergency Department

Recruiting
N/A
100
Europe
Laryngotracheal Aspiration Procedure Using a Probe in the Emergency Department, Aspiration Procedure Using Fibrobronchoscopy in the Emergency Department
Azienda Ospedaliero-Universitaria Careggi
Aspiration Pneumonia, Bronchoscopy
02/27
03/27
HCAPPED-I, NCT06506617: HCAPPED I: HCAP-Pcr in Emergency Department

Recruiting
N/A
93
Europe
Azienda Ospedaliero-Universitaria Careggi
Pneumonia, Bronchoalveolar Lavage, Antimicrobial Treatment, Sputum
07/25
01/26
Masi, Salvatore De
REGRASP, NCT06620536: Restoring Hand Function in Patients with Tetraplegia by Intraneural Stimulation of Peripheral Nerves

Not yet recruiting
N/A
2
Europe
Electrical stimulation
Azienda Ospedaliero-Universitaria Careggi, Scuola Superiore Sant'Anna di Pisa
Tetraplegics
01/25
12/26

Download Options